Distinct isoforms, including CD44s, CD44v, and soluble CD44, contribute to tumor initiation, invasion, therapy resistance, and immune dysregulation through interactions with HA, osteopontin, growth factor receptors, and proteases. The gene discussed is SPP1; the disease is neoplasm.